SRR1489971
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.448
- IL6_JAK_STAT3_SIGNALING+0.440
- ALLOGRAFT_REJECTION+0.400
- INTERFERON_ALPHA_RESPONSE+0.388
- KRAS_SIGNALING_DN+0.379
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.359
- MYOGENESIS+0.354
- INTERFERON_GAMMA_RESPONSE+0.326
- COAGULATION+0.323
- COMPLEMENT+0.315
Top 10 suppressed
- MYC_TARGETS_V2-0.641
- MYC_TARGETS_V1-0.635
- OXIDATIVE_PHOSPHORYLATION-0.631
- DNA_REPAIR-0.508
- UNFOLDED_PROTEIN_RESPONSE-0.508
- PROTEIN_SECRETION-0.476
- MTORC1_SIGNALING-0.470
- E2F_TARGETS-0.464
- G2M_CHECKPOINT-0.418
- ADIPOGENESIS-0.291
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1397906 | GTEX | — | 0.957 |
| 2 | SRR1500800 | GTEX | — | 0.948 |
| 3 | SRR1394297 | GTEX | — | 0.948 |
| 4 | SRR1358826 | GTEX | — | 0.945 |
| 5 | SRR1078347 | GTEX | — | 0.944 |
| 6 | SRR600724 | GTEX | — | 0.943 |
| 7 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.943 |
| 8 | SRR1472770 | GTEX | — | 0.942 |
| 9 | SRR1468141 | GTEX | — | 0.941 |
| 10 | SRR598894 | GTEX | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.448 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.388 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.379 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.359 | Inavolisib | — uncovered |
| MYOGENESIS | 0.354 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.326 | Idelalisib | — uncovered |
| COAGULATION | 0.323 | Binimetinib | — uncovered |
| COMPLEMENT | 0.315 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.313 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.257 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.251 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.239 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.234 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.233 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.224 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.195 | Idelalisib | — uncovered |
| HYPOXIA | 0.161 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.154 | Inavolisib | — uncovered |